Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent vs Sequential HAIC + Lenvatinib + PD-1 Antibody in HCC
NCT06041477Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Oct 2023; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06041477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041477.